Sichuan Biokin Stock Hits Day Low Amid Price Pressure, Closing at CNY 239.06

Sichuan Biokin Pharmaceutical Co., Ltd. experienced a notable decline today, with the stock dropping by 4.01% to reach an intraday low of CNY 239.06. This performance stands in contrast to the China Shanghai Composite, which gained 0.87% on the same day. Over the past week, Sichuan Biokin has seen a decrease of 6.6%, while its monthly performance reflects a significant drop of 18.74%. Year-to-date, the stock has declined by 25.7%, contrasting sharply with the Shanghai Composite's positive return of 3.63%. The company's financial metrics indicate challenges, with net sales for the first nine months showing a decline of 63.52%, and a net profit loss of CNY 500.37 million, marking a 112.34% decrease. Additionally, the operating cash flow has reached a low of CNY -2,331.46 million. Despite a three-year performance increase of 150.98%, the current financial landscape suggests a difficult period for Sichuan Biokin, as it navigates through a challenging market environment.